FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2168074233> ?p ?o ?g. }

• W2168074233 abstract "Abstract Background Astrocytomas are largely dependent on glycolysis to satisfy their bioenergetic requirements for growth and survival. Therapies that target glycolysis can potentially manage astrocytoma growth and progression. Dietary restriction of the high fat/low carbohydrate ketogenic diet (KD-R) reduces glycolysis and is effective in managing experimental mouse and human astrocytomas. The non-metabolizable glucose analogue, 2-deoxy-D-glucose (2-DG), is a potent glycolytic inhibitor that can mimic effects of energy restriction both in vitro and in vivo , but can also produce adverse effects when administered at doses greater than 200 mg/kg. The goal here was to determine if low doses of 2-DG could act synergistically with the KD-R to better manage growth of the CT-2A malignant mouse astrocytoma. Methods The therapeutic effect of a KD-R supplemented with a low dose of 2-DG (25 mg/kg) was examined in adult C57BL/6J mice bearing the syngeneic CT-2A malignant astrocytoma grown orthotopically. Mice were fed the standard unrestricted diet for the first 3 days after tumor implantation prior to their separation into one of four diet groups fed either a standard rodent diet in unrestricted amounts (SD-UR) or a KD-R with or without 2-DG for 10 days. The KD-R was restricted to reduce body weight by about 20%. 2-DG was initiated 6 days after tumor implantation and was continued for 7 days. Brain tumors were excised and weighed. Results Energy intake, body weights, and CT-2A tumor weights were similar in the SD-UR and the SD-UR+2-2DG mouse groups over the dietary treatment period (days 3–13). Tumor weights were about 48% and 80% lower in the KD-R and in the KD-R+2-DG groups, respectively, than in the SD-UR group. Mouse health and vitality was better in the KD-R group than in the KD-R+2-DG group. Conclusion Astrocytoma growth was reduced more in the KD-R mouse group supplemented with 2-DG than in the mouse groups receiving either dietary restriction or 2-DG alone, indicating a synergistic interaction between the drug and the diet. The results suggest that management of malignant astrocytoma with restricted ketogenic diets could be enhanced when combined with drugs that inhibit glycolysis." @default.
• W2168074233 created "2016-06-24" @default.
• W2168074233 creator A5021162065 @default.
• W2168074233 creator A5053210792 @default.
• W2168074233 creator A5057571164 @default.
• W2168074233 date "2008-11-25" @default.
• W2168074233 modified "2023-09-23" @default.
• W2168074233 title "Drug/diet synergy for managing malignant astrocytoma in mice: 2-deoxy-D-glucose and the restricted ketogenic diet" @default.
• W2168074233 cites W106744990 @default.
• W2168074233 cites W1599336280 @default.
• W2168074233 cites W1606666119 @default.
• W2168074233 cites W1862828191 @default.
• W2168074233 cites W1977130471 @default.
• W2168074233 cites W1983823883 @default.
• W2168074233 cites W1994731715 @default.
• W2168074233 cites W2003337414 @default.
• W2168074233 cites W2014947296 @default.
• W2168074233 cites W2041073833 @default.
• W2168074233 cites W2048269119 @default.
• W2168074233 cites W2054172055 @default.
• W2168074233 cites W2054553927 @default.
• W2168074233 cites W2056003871 @default.
• W2168074233 cites W2072451938 @default.
• W2168074233 cites W2081982894 @default.
• W2168074233 cites W2083741341 @default.
• W2168074233 cites W2092752244 @default.
• W2168074233 cites W2093960344 @default.
• W2168074233 cites W2094585672 @default.
• W2168074233 cites W2104382375 @default.
• W2168074233 cites W2112144930 @default.
• W2168074233 cites W2118980450 @default.
• W2168074233 cites W2158955581 @default.
• W2168074233 cites W2169033880 @default.
• W2168074233 cites W2170716148 @default.
• W2168074233 cites W2914002569 @default.
• W2168074233 doi "https://doi.org/10.1186/1743-7075-5-33" @default.
• W2168074233 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2607273" @default.
• W2168074233 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19032781" @default.
• W2168074233 hasPublicationYear "2008" @default.
• W2168074233 type Work @default.
• W2168074233 sameAs 2168074233 @default.
• W2168074233 citedByCount "75" @default.
• W2168074233 countsByYear W21680742332012 @default.
• W2168074233 countsByYear W21680742332013 @default.
• W2168074233 countsByYear W21680742332014 @default.
• W2168074233 countsByYear W21680742332015 @default.
• W2168074233 countsByYear W21680742332016 @default.
• W2168074233 countsByYear W21680742332017 @default.
• W2168074233 countsByYear W21680742332018 @default.
• W2168074233 countsByYear W21680742332019 @default.
• W2168074233 countsByYear W21680742332020 @default.
• W2168074233 countsByYear W21680742332021 @default.
• W2168074233 countsByYear W21680742332022 @default.
• W2168074233 countsByYear W21680742332023 @default.
• W2168074233 crossrefType "journal-article" @default.
• W2168074233 hasAuthorship W2168074233A5021162065 @default.
• W2168074233 hasAuthorship W2168074233A5053210792 @default.
• W2168074233 hasAuthorship W2168074233A5057571164 @default.
• W2168074233 hasBestOaLocation W21680742331 @default.
• W2168074233 hasConcept C100206155 @default.
• W2168074233 hasConcept C118552586 @default.
• W2168074233 hasConcept C126322002 @default.
• W2168074233 hasConcept C134018914 @default.
• W2168074233 hasConcept C150903083 @default.
• W2168074233 hasConcept C17093226 @default.
• W2168074233 hasConcept C20251656 @default.
• W2168074233 hasConcept C207001950 @default.
• W2168074233 hasConcept C2778186239 @default.
• W2168074233 hasConcept C2778227246 @default.
• W2168074233 hasConcept C2778587478 @default.
• W2168074233 hasConcept C2778880634 @default.
• W2168074233 hasConcept C28859421 @default.
• W2168074233 hasConcept C502942594 @default.
• W2168074233 hasConcept C55493867 @default.
• W2168074233 hasConcept C62231903 @default.
• W2168074233 hasConcept C71924100 @default.
• W2168074233 hasConcept C86803240 @default.
• W2168074233 hasConcept C98274493 @default.
• W2168074233 hasConceptScore W2168074233C100206155 @default.
• W2168074233 hasConceptScore W2168074233C118552586 @default.
• W2168074233 hasConceptScore W2168074233C126322002 @default.
• W2168074233 hasConceptScore W2168074233C134018914 @default.
• W2168074233 hasConceptScore W2168074233C150903083 @default.
• W2168074233 hasConceptScore W2168074233C17093226 @default.
• W2168074233 hasConceptScore W2168074233C20251656 @default.
• W2168074233 hasConceptScore W2168074233C207001950 @default.
• W2168074233 hasConceptScore W2168074233C2778186239 @default.
• W2168074233 hasConceptScore W2168074233C2778227246 @default.
• W2168074233 hasConceptScore W2168074233C2778587478 @default.
• W2168074233 hasConceptScore W2168074233C2778880634 @default.
• W2168074233 hasConceptScore W2168074233C28859421 @default.
• W2168074233 hasConceptScore W2168074233C502942594 @default.
• W2168074233 hasConceptScore W2168074233C55493867 @default.
• W2168074233 hasConceptScore W2168074233C62231903 @default.
• W2168074233 hasConceptScore W2168074233C71924100 @default.
• W2168074233 hasConceptScore W2168074233C86803240 @default.
• W2168074233 hasConceptScore W2168074233C98274493 @default.
• W2168074233 hasIssue "1" @default.
• W2168074233 hasLocation W21680742331 @default.
• W2168074233 hasLocation W21680742332 @default.

• next